ALX Oncology is laying off 30% of its staff, mainly in preclinical research, to redirect money toward clinical trials, ...

In this article, we are going to take a look at where ALX Oncology Holdings Inc. (NASDAQ:ALXO) stands against the other stocks. The stock market pulled back to the red territory on Thursday ...

ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker evorpacept and planned entry into the clinic of its novel ...

ALX Oncology announced promising results from the ASPEN-06 Phase 2 clinical trial of its CD47-blocker, evorpacept, at the 2025 ASCO Gastrointestinal Cancers Symposium. This investigational ...

ALX Oncology stock opened at $1.03 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. ALX Oncology has a 52 week low of $0.96 and a 52 ...

ALX Oncology Holdings, Inc. (“ALX Oncology” or the “Company”), (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and ...